Brentuximab vedotin is both active and well tolerated in cutaneous T-cell lymphoma and lymphatoid papulosis, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
Brentuximab vedotin is a CD30-directed antibody-drug conjugate approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
For the open-label phase II study, researchers enrolled 48 patients with CD30+ lymphoproliferative disorders or mycosis fungoides. All patients received brentuximab vedotin 1.8 mg/kg intravenously every 21 days.
Results showed an overall response rate of 73% (95% CI: 60, 86) and a complete response rate of 35% (95% CI: 22, 49) among the 48 evaluable patients.
Of the 28 patients with mycosis fungoides, 54% (95% CI: 331, 59) responded to brentuximab vedotin treatment, independent of CD30 expression.
Researchers also found that all patients with primary cutaneous anaplastic T-cell lymphomas and lymphomatoid papulosis responded to treatment with a median duration of response of 26 weeks.
In regard to safety, 65% of patients experienced grade 1 to 2 peripheral neuropathy, but resolved in 45% of those who reported it in a median of 41.5 weeks. Grade 3 to 4 adverse events included neutropenia, nausea, and chest pain.
Preliminary findings were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA, in 2013.
- Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015. [epub ahead of print]. doi: 10.1200/JCO.2014.60.3787.